Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of rozibafusp alfa in active systemic lupus erythematosus with inadequate response to standard of care
jRCT2080225306Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Peptides
01
Overview
Phase 2, randomised trial of rozibafusp alfa in systemic lupus erythematosus (SLE) (4 arms), sponsored by Amgen. Started Aug 2020; status: completed.
02
Drugs
rozibafusp alfa
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080225306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225306.